AOD-9604 is a 16-amino-acid fragment of human growth hormone, and the community runs it mainly for targeted fat loss, with a smaller group using it for cartilage and joint repair; reports on both skew positive. Clinician protocols dose 250 to 500 mcg daily subcutaneously, often over eight-to-twenty-four-week runs, and some pair it with other peptides for fat loss, though most community posters don't state their own schedule. The honest caveat: there's no FDA-approved indication, so every human use is off-label or compounded.
Data last updated
Measured on 5 of 6 axes
Evidence shape
AOD-9604 possesses low-tier evidence, supported by only a single exploratory human study focused on treatment outcomes. The clinical literature remains thin, as there are no registered trials or completed large-scale studies to validate its efficacy or safety profile. This lack of formal trial data means the peptide exists primarily as a long-tail research interest, with no established clinical consensus or robust evidence base to support its use for any specific indication.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How AOD-9604 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
The research‑tier for AOD‑9604 notes subcutaneous administration, but only one human study is cited and no reliable dose amount, frequency, or cycling is reported.
No structured protocol details captured for this tier yet.
Most reports did not specify a frequency; among those that did, daily dosing at about 300 mcg was most common (5 reports), while single reports noted every‑other‑day or weekly use (500 mcg–14 mg).